Immunological Backbone of Uveal Melanoma: Is There a Rationale for Immunotherapy?
Ernesto RossiGiovanni SchinzariIlaria Grazia ZizzariBrigida Anna MaioranoMonica Maria PagliaraMaria Grazia SammarcoVincenzo FiorentinoGianluigi PetroneAlessandra CassanoGuido RindiEmilio BriaMaria Antonietta BlasiMarianna NutiGiampaolo TortoraPublished in: Cancers (2019)
No standard treatment has been established for metastatic uveal melanoma (mUM). Immunotherapy is commonly used for this disease even though UM has not been included in phase III clinical trials with checkpoint inhibitors. Unfortunately, only a minority of patients obtain a clinical benefit with immunotherapy. The immunological features of mUM were reviewed in order to understand if immunotherapy could still play a role for this disease.
Keyphrases
- clinical trial
- phase iii
- end stage renal disease
- open label
- newly diagnosed
- ejection fraction
- small cell lung cancer
- phase ii
- chronic kidney disease
- dna damage
- peritoneal dialysis
- prognostic factors
- cell cycle
- double blind
- randomized controlled trial
- patient reported outcomes
- oxidative stress
- study protocol
- cell proliferation